Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
MetaVia's DA-1726, a 3:1 ratio GLP-1/glucagon dual receptor agonist, demonstrated maximum weight loss of 6.3% and mean reduction of 4.3% after just 26 days in Phase 1 trial without dose titration.
NeuroBo Pharmaceuticals announced positive top-line data from the Phase 1 clinical trial of DA-1726 for obesity.
NeuroBo Pharmaceuticals completed enrollment in the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726 for obesity.